Stručni rad
https://doi.org/10.20471/acc.2024.63.s2.13
Prostate Cancer Theranostics – Current Evidence and Future Considerations: a Brief Overview
Antonela Njavro
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Jure Murgić
orcid.org/0000-0001-8152-0494
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
*
Blanka Jakšić
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Marin Prpić
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
Angela Prgomet Sečan
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Dražen Huić
; Clinical Department of Nuclear Medicine and Radiation Protection, Zagreb University Hospital Centre, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Dinko Franceschi
; Department of Radiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA
Ana Fröbe
; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
* Dopisni autor.
Sažetak
Despite initial response to androgen inhibition, metastatic prostate cancer is invariably
an incurable disease. New agents with different mechanisms of action are needed that are capable of
producing clinical benefit and prolonging survival. New breakthroughs specific to prostate cancer are being
made by combining novel diagnostic molecular imaging modalities with cytotoxic radionuclide payloads
to cancer cells and the surrounding tumor microenvironment. This concept yielded unprecedented
clinical responses in a very challenging population of patients. Targeted radionuclide therapy, mainly
targeting prostate-specific antigen (PSMA), is now considered the new standard of care for patients
with advanced disease who have progressed to the use of new androgen suppressors and chemotherapy.
Targeted radionuclide therapy, mainly focused on prostate-specific antigen, is now considered the new
treatment standard for patients with more aggressive disease who have been treated with new androgen
suppressors and chemotherapy. The application of the theranostic paradigm has enabled personalized
management of prostate cancer patients, with significant potential for future development in the form
of a combination therapy with other agents. This freeform review article summarizes the key clinical
research in the field of radionuclide targeted therapy for prostate cancer and provides an overview of
current practice in this rapidly evolving entity.
Ključne riječi
Prostate-specific membrane antigen (PSMA); Peptide; Radionuclide; Radiotherapy; Alpha particle; Prostate cancer; Castration resistance
Hrčak ID:
323263
URI
Datum izdavanja:
30.4.2024.
Posjeta: 0 *